AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02054000 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intracoronary serum physiologic
Study NCT00022490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Once daily subcutaneous injection of Ara-C (Cytarabine) at a dose of 20 mg (10 mg or 5 mg if they have been dose reduced) per square meter of calculated body surface area, on days 15-28 of each sequential 28 day cycle
Study NCT00022490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Once daily oral administration of STI571 (Imatinib Mesylate) at a dose of 400 mg for 12 months.
Study NCT03786887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: dosage of nalbuphine
Study NCT00237978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalen
Study NCT03881137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric assessment with management
Description: A multicomponent intervention, carried out in cooperation between hospital and community services, based on a geriatric assessment (GA) followed by individually adapted measures targeting identified needs.~The GA and the start of the intervention will be handled by a PhD student (geriatrician) or project cancer nurse at start of RT. Pre-planned guidelines will be followed. Contribution from relevant hospital professionals will be sought according to needs. Then the intervention will be offered in the primary health care taking advantage of existing services, e.g. home care, rehabilitation services, exercise groups etc. A community-based coordinating nurse will follow the patients with weekly contacts throughout RT and to end of intervention 8 weeks post-RT. To ensure that each patient's intervention is properly adjusted to changing needs, repeated clinical assessments will be performed by the end of RT and 4 weeks post-RT.
Study NCT02221258 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FURESTEM-RA Inj.
Description: Patients will be treated FURESTEM-RA Inj.+DMARDs(Disease-Modifying antirheumatic drugs)
Study NCT00237978 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: VIS and wIRA
Study NCT02172807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium low
Description: Tiotropium 18 µg inhalation capsule
Study NCT02172807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium high
Description: Tiotropium 36 µg inhalation capsule
Study NCT02172807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo MDI
Description: Placebo metered dose inhaler (MDI)
Study NCT00526760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study NCT02917369 — intervention group
Intervention type: OTHER
Intervention: Normal lung tissue
Description: The investigators will extract total protein, DNA and RNA from LCLC patients.
Study NCT02172807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo inhalation capsule
Study NCT02172807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxitropium
Description: Oxitropium MDI (100 µg/puff)
Study NCT00473590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg administered by intravenous infusion
Study NCT00473590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m\^2 administered by intravenous bolus injection
Study NCT03278834 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular muscle stimulation machine- Strength Setting
Description: Muscle stimulation to strength skeletal muscle
Study NCT03278834 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neuromuscular muscle stimulation machine - TENS Setting
Description: Muscle stimulation to mimic the intervention but without the strength gains.
Study NCT00473590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: 1.3 mg/m\^2 administered by intravenous bolus injection
Study NCT00473590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Intravenous repeating dose
Study NCT03653988 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEC I/II blocks by anesthesiologist - pre-operative
Description: PEC I/II blocks by anesthesiologist - pre-operative; PEC I/II block to anesthetize the pectoral, intercostobrachial, third to sixth intercostal and long thoracic nerves. The PEC I/II blocks are pectoralis field blocks where local anesthetic medication is injected under ultrasound guidance between the tissue planes of pectoralis major and minor muscles (PECS I) and in the plane of the serratus anterior muscle at the level of the third rib (PEC II). Group I will have the PEC block administered by the anesthesiologist prior to surgical incision.
Study NCT01130662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination therapy using decitabine and midostaurin
Description: Cohort 1:~Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 25mg bid days 8-21 of each cycle.~Cohort 2:~Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 50mg bid days 8-21 of each cycle.~Cohort 3:~Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 50mg bid x 28 days of each cycle.
Study NCT04578405 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis
Description: Anastomosis performed totally laparoscopically
Study NCT04578405 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal anastomosis
Description: Anastomosis performed through a minilaparotomy
Study NCT02345876 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT03653988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEC I/II blocks by surgeon - intra-operative
Description: PEC I/II blocks by surgeon - intra-operative; PEC I/II block to anesthetize the pectoral, intercostobrachial, third to sixth intercostal and long thoracic nerves. The PEC I/II blocks are pectoralis field blocks where local anesthetic medication is injected under ultrasound guidance between the tissue planes of pectoralis major and minor muscles (PECS I) and in the plane of the serratus anterior muscle at the level of the third rib (PEC II).
Study NCT01251835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitaxsentan alone
Description: Days 1-5: Sitaxsentan tablet, 100 mg, q24 h (once a day)
Study NCT01605747 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Culturelle
Description: one capsule 2x per day per feeding tube
Study NCT01251835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxsentan
Description: Days 6-12: Sitaxsentan tablet, 100 mg, q24h (once a day)
Study NCT01251835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Days 6-12: Rifampin capsule, 600 mg, q24h (once a day)
Study NCT02585921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Interventions
Description: Participants will watch 2 5-minute videos and then discuss them as a group.
Study NCT02585921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Donation Discussion Education
Description: Participants will learn techniques for introducing and discussing organ donation with parents and guardians.
Study NCT04519346 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: intradermal injection
Description: Mesotherapy was performed by an experienced and trained physician using disposable 4 mm and 6 mm long 30 Gauge needles (Meso-relle, Biotekne SRL, Italy)to the pericarotid region, glabella, and the area between the eyes and ears, and to the area of the head where pain occurred (such as frontal, parietal, occipital region) for each patient
Study NCT01157026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol Rich Fraction (TRF)
Description: Tocotrienol Rich Fraction (200mg), daily for five years
Study NCT01157026 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo plus tamoxifen
Description: 20mg tamoxifen daily
Study NCT02522325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phendimetrazine
Description: Phendimetrazine will be administered in divided doses twice daily.
Study NCT01485809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250mg/day, oral daily q every 4 weeks
Study NCT05192902 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Computer-controlled Local Anaesthesia (CCLA)
Description: The computer-controlled local anesthetic injector Calaject®, (Rønvig Dental MFG, Daugaard, Denmark), which is designed to reduce the pain of performing local anaesthesia. The principle of this device is based on the fact that the less pressure and flow of a local anaesthetic injection, the less painful will be the procedure. Each device has an installed pressure sensor as well as a three-button display that allows choosing the most appropriate program in terms of different speeds and pressure. According to the anaesthesia technique, the manufacture recommends program I for intraligamentary and palatally injections, program II for infiltration and III for alveolar nerve block techniques. Conventional carpules and needles can be used in a pen-shaped part connecting to the main unit. The administration of the anaesthetic can be achieved using a foot control pedal which is adapted to the main unit, the speed of injection is related to acoustic signals.
Study NCT05192902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer-controlled Local Anaesthesia (CCLA)
Description: The computer-controlled local anesthetic injector Calaject®, (Rønvig Dental MFG, Daugaard, Denmark), which is designed to reduce the pain of performing local anaesthesia. The principle of this device is based on the fact that the less pressure and flow of a local anaesthetic injection, the less painful will be the procedure. Each device has an installed pressure sensor as well as a three-button display that allows choosing the most appropriate program in terms of different speeds and pressure. According to the anaesthesia technique, the manufacture recommends program I for intraligamentary and palatally injections, program II for infiltration and III for alveolar nerve block techniques. Conventional carpules and needles can be used in a pen-shaped part connecting to the main unit. The administration of the anaesthetic can be achieved using a foot control pedal which is adapted to the main unit, the speed of injection is related to acoustic signals.
Study NCT05192902 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Local Anaesthesia
Description: Conventional dental local anaesthetic injections.
Study NCT01605747 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one placebo 2x per day per feeding tube
Study NCT04647903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADAIR 10 mg IR tablets
Description: manipulated ADAIR 3x10mg
Study NCT04647903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: d-amphetamine sulfate
Description: crushed d-amphetamine sulfate 3x10mg
Study NCT02522325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: Intranasal cocaine will be administered during experimental sessions.
Study NCT02522325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine
Description: Intranasal cocaine will be administered during experimental sessions.
Study NCT04647903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo for oral and intranasal administration
Study NCT04647903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo for oral and intranasal administration
Study NCT02522325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will contain only cornstarch.
Study NCT04657809 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Insulin film
Description: Insulin suspension vials
Study NCT04657809 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Insulin film
Description: Insulin suspension vials
Study NCT04657809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fast dissolving film
Description: Fast dissolving film
Study NCT04647903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo for oral and intranasal administration
Study NCT04657809 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fast dissolving film
Description: Fast dissolving film
Study NCT03328572 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-max Endocrown
Description: Endocrown preparation
Study NCT03328572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerasmart Endocrown
Description: Endocrown preparation
Study NCT04994860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-1058
Description: Oral BIA 5-1058 (Zamicastat) 100 mg tablets
Study NCT03127514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMX0035
Description: AMX0035
Study NCT03127514 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Comparator
Study NCT05596656 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: skin prick test
Description: Skin prick testing was performed to all diabetic child with history of allergy. The recommended method of prick testing includes the appropriate use of specific allergen extracts, positive and negative controls, interpretation of the tests after 15 - 20 minutes of application, with a positive result defined as a wheal ≥3 mm diameter more than negative control for detection of specific IgE to one or more of common aeroallergens.~The location of each allergen was marked with a pen on the volar aspect of forearm to properly identify test results, at least 2 cm from the wrist and the antecubital fossae. The distance between two skin prick tests should be appropriate to avoid false-positive reactions due to direct contamination of a nearby test. A drop of each test solution should be placed on the skin in identical order for each subject tested and immediately pricked with a single-head metal lancet.
Study NCT00269425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: American Heart Association Step 2 diet
Description: Low fat diet with patient education and diet analysis
Study NCT00269425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: Mediterranean style diet with patient education and diet analysis
Study NCT03505086 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood withdrawal
Description: * Blood withdrawal will be at regular sampling moments, blood can be collected from a central venous catheter or venepuncture procedure.~* Blood withdrawal will be performed for a maximum of 10 times per admission, 10 ml per time.~* Urine sampling will be for a maximum of 5 times per admission.~* Urine can be sampled from a catheter when present, or collected regular.
Study NCT04994860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Oral Sildenafil ( Revatio) 20 mg film coated tablets
Study NCT04994860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Oral Sildenafil ( Revatio) 20 mg film coated tablets
Study NCT03505086 — intervention group
Intervention type: OTHER
Intervention: Questionnaire for former bleeding events
Description: Questionnaire to investigate a bleeding tendency before diagnosis.
Study NCT03193281 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dasatinib
Description: In order to test the study hypothesis patients need to stay on dasatinib (Sprycel) treatment for the first 12 months of the study (Stage 1).~Patients who do not reach MR3.0 at 12 months will remain on dasatinib treatment.
Study NCT03193281 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Imatinib
Description: Patients who reach MR3.0 at 12 months (and the result is confirmed at 13 months) will switch to imatinib (Imatinib-AFT) treatment.
Study NCT00603369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group intervention
Description: 13-session intervention
Study NCT00603369 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: group intervention
Description: 2-session intervention
Study NCT02237586 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: live, aseptic, cryopreserved P. falciparum sporozoites
Study NCT01130493 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IPX066
Description: experimental product
Study NCT01130493 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CLE
Description: active comparator
Study NCT03616457 — intervention group
Intervention type: DEVICE
Intervention: Automated Breast Ultrasound (ABUS)
Description: Participants will undergo imaging with ABUS.
Study NCT03000062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Please see the preceding section
Study NCT00042601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramlintide acetate
Description: Pramlintide injection will be supplied in 5-mL multidose glass vials with rubber stoppers.
Study NCT00042601 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo injection will be supplied in 5-mL multidose glass vials with a rubber stopper
Study NCT03408171 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 19-gauge FNA needle
Description: A 19-gauge FNA needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNB needle.
Study NCT03408171 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 19-gauge FNB needle
Description: A 19-gauge FNB needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNA needle.
Study NCT03064724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Mobile Doctor (iMD)
Description: iMD delivers tailored interactive video education via a mobile tablet to smoking patients right before their clinic visit with a provider. iMD delivers the 5 A's (ask, advise, assess, assist, and arrange) and generates a bilingual tailored printout, which aims to increase patient-provider discussion on tobacco use and to promote smoking cessation. This version of iMD delivers the intervention in Korean or Vietnamese languages as preferred by the patient.
Study NCT00307086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bortezomib
Description: the maximum tolerated dose (MTD) of bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous stem cell transplant
Study NCT00307086 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Melphalan
Description: Day -4 melphalan 100 mg/m2 intravenously over 30 minutes, Day -3 melphalan 100 mg/m2 intravenously over 30 minutes
Study NCT00307086 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: PBSCT
Description: PBSCT #1 Day 0 PBSCT #2 Day 0 (approx 90 days =/- 15 days after PBSCT #1)
Study NCT03618017 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CCC website
Description: ConnectedCancerCare (CCC) is a web-based guide to support survivorship care for women who have been treated for early-stage (stages 0-II) breast cancer. It encourages patients to utilize team-based care by oncologists and primary care physicians and provides them with the information on cancer surveillance, screenings and preventive healthcare during survivorship.
Study NCT03618017 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Static care plan
Description: The control is a static survivorship care plan template in PDF format that includes information similar to what an oncologist currently provides as standard of care.
Study NCT05190939 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: water as bladder distending media
Description: water will be used for bladder dissension during cystoscopy
Study NCT05190939 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: intravenous dye
Description: intravenous dye using methylene blue or fluorescein will be used for visual aid of ureteral jets during cystoscopy
Study NCT05190939 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: Saline only, no dye
Study NCT03032848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conjugated Estrogen
Description: use of 1 gram per day
Study NCT03032848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Conjugated Estrogen
Description: use of 1 gram per day
Study NCT03032848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Promestriene
Description: use of 1 gram per day
Study NCT03032848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Promestriene
Description: use of 1 gram per day
Study NCT03032848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estriol
Description: use of 1 gram per day
Study NCT03032848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estriol
Description: use of 1 gram per day
Study NCT03032848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Moisturizer - Cream
Description: use of 1 gram per day
Study NCT03732430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI308
Description: A humanized anti-PD-1 monoclonal antibody